# MedBridge Pediatrics — Full Knowledge File

> MedBridge Pediatrics is the pediatric subsite of MedBridge Shanghai (美加康医疗), coordinating children's care in China for international families. Trilingual site (English /en, Russian /ru, Chinese /zh); every page has hreflang alternates and JSON-LD structured data. All facts below are verifiable against the public pages linked per entity.

## Related MedBridge sites
- Pediatric care (this site): https://kids.mjktrip.com
- Adult oncology, CAR-T for adults, proton/carbon-ion, BNCT: https://cnco.mjktrip.com
- Patient entry site, full service catalogue: https://www.mjktrip.com
- Hospital / insurer / corporate cooperation (B2B): https://brand.mjktrip.com

## Core Services & Facts
- Free expert case review: submit the form at any locale home page (#case-review); a pediatric coordination team replies within 24 hours.
- Typical pathway: case review (48h written opinion) → MDT plan & transparent estimate → medical visa & travel support → in-hospital bilingual coordination → remote follow-up.
- Contact: WhatsApp +86 138 1783 1623. Service languages: 12, including English, Russian and Chinese.
- No waiting lists — specialist appointment typically within 3–5 working days.
- Medical fees are paid directly to hospitals; MedBridge never handles them.

## Reference Treatment Costs (China vs. US/Europe)
- Pediatric CAR-T cell therapy (CD19): China ¥1.0M – 1.3M vs international $400K – 500K+ — saving ≈ 65%
- Haploidentical HSCT (all-inclusive): China ¥300K – 500K vs international $300K – 800K — saving ≈ 80%
- Proton therapy (full course): China ¥278K – 350K vs international $80K – 150K — saving ≈ 60%
- Congenital heart surgery (arterial switch / TOF): China ¥150K – 250K vs international $150K – 400K — saving ≈ 85%
- Retinoblastoma intra-arterial chemo (per cycle): China ¥30K – 60K vs international $15K – 45K — saving ≈ 70%
- MDT consultation & second opinion: China ¥3,000 – 8,000 vs international $3,000 – 10,000 — saving ≈ 90%
- Note: * Reference ranges based on standard clinical pathways; a formal quotation follows the hospital's assessment. Medical fees are paid directly to the hospital — we never handle them.

## Departments
- [Hematology & Oncology Center](https://kids.mjktrip.com/en/departments/hematology-oncology): Leukemia, lymphoma, transplant & cellular therapy
- [Cardiothoracic Surgery Center](https://kids.mjktrip.com/en/departments/cardiothoracic-surgery): Complex congenital heart repair, from 2 kg newborns
- [Neurology & Epilepsy Center](https://kids.mjktrip.com/en/departments/neurology-epilepsy): Drug-resistant epilepsy evaluation & surgery
- [Neonatology & NICU](https://kids.mjktrip.com/en/departments/neonatology-nicu): Level III intensive care for the tiniest fighters
- [Solid Tumor Center & Surgery](https://kids.mjktrip.com/en/departments/solid-tumor-surgery): Neuroblastoma, Wilms tumor, hepatoblastoma & sarcoma
- [Pediatric Ophthalmology](https://kids.mjktrip.com/en/departments/ophthalmology): Eye-saving retinoblastoma therapy & pediatric vision
- [Gastroenterology & Nutrition](https://kids.mjktrip.com/en/departments/gastroenterology): Pediatric endoscopy, IBD & feeding rehabilitation
- [Respiratory & Allergy Center](https://kids.mjktrip.com/en/departments/respiratory-allergy): Asthma, chronic cough & immunotherapy
- [Pediatric Orthopedics](https://kids.mjktrip.com/en/departments/orthopedics): Scoliosis, hip dysplasia & limb reconstruction
- [Child Healthcare & Development](https://kids.mjktrip.com/en/departments/child-healthcare): Growth, development & preventive pediatrics
- [Pediatric Dentistry](https://kids.mjktrip.com/en/departments/dentistry): Gentle dental care, sedation & early orthodontics
- [Traditional Chinese Medicine](https://kids.mjktrip.com/en/departments/tcm-pediatrics): Integrative support through treatment & recovery

## Doctors (verified specialists)
- [Prof. Wu Minyuan](https://kids.mjktrip.com/en/doctors/wu-minyuan): Professor & Chief Expert · Hematology-Oncology Center — Childhood Leukemia & Pediatric Hematology. Beijing Jingdu Children's Hospital, Beijing. 50 years of experience. Clinic: Mon & Wed AM · Chief Expert Clinic (Hematology). Honors: Founded the CCLG childhood ALL collaborative network (2008) and authored China's national clinical pathway for childhood leukemia; Her BCH-98 / BCH-03 / BCH-05 protocols raised childhood ALL 5-year disease-free survival from ~70% to 82%.
- [Prof. Wang Tianyou](https://kids.mjktrip.com/en/doctors/wang-tianyou): Professor (Grade II) · Renowned Expert in Pediatric Hematology — Pediatric Hematology & Histiocytic Disorders. Beijing Children's Hospital, Capital Medical University, Beijing. 40 years of experience. Clinic: Wed AM · Renowned Expert Clinic (Hematology). Honors: Immediate Past President, Chinese Society of Pediatrics, Chinese Medical Association; Editor-in-Chief, Chinese Journal of Pediatrics; Editor-in-Chief, Chinese Journal of Pediatric Hematology & Oncology.
- [Prof. Sun Yuan](https://kids.mjktrip.com/en/doctors/sun-yuan): Professor · President & Director of Hematology-Oncology — Pediatric HSCT & Cord Blood Transplantation. Beijing Jingdu Children's Hospital, Beijing. 30 years of experience. Clinic: Tue & Thu AM · President's Special Clinic. Honors: Nearly 30 years in pediatric HSCT — matched-sibling, haploidentical, unrelated & cord-blood grafts; National authority on transplantation for HLH, chronic active EBV & primary immunodeficiency.
- [Prof. Tang Jingyan](https://kids.mjktrip.com/en/doctors/tang-jingyan): Professor · Doctoral Supervisor, Hematology-Oncology — Pediatric Solid Tumors & Lymphoma (MDT). Shanghai Children's Medical Center, SJTU, Shanghai. 38 years of experience. Clinic: Tue AM · Special Needs Clinic (Hematology-Oncology). Honors: Immediate Past Chair, Pediatric Oncology Committee, China Anti-Cancer Association; Director, NHC Key Laboratory for Pediatric Hematology & Oncology; Deputy Head, Hematology Group, Chinese Society of Pediatrics.
- [Prof. Chen Jing](https://kids.mjktrip.com/en/doctors/chen-jing): Professor · Director, Hematology-Oncology Department — Pediatric HSCT & CAR-T Cellular Therapy. Shanghai Children's Medical Center, SJTU, Shanghai. 30 years of experience. Clinic: Thu AM · Special Needs Clinic (Transplant & Cellular Therapy). Honors: Nearly 2,000 pediatric hematopoietic stem cell transplants completed by her team; Performed China's first autologous stem cell transplant for refractory pediatric SLE.
- [Prof. Zhai Xiaowen](https://kids.mjktrip.com/en/doctors/zhai-xiaowen): Professor · Vice President; Academic Lead of Hematology — Pediatric HSCT for Rare Diseases & Thalassemia. Children's Hospital of Fudan University, Shanghai. 28 years of experience. Clinic: Tue AM · Special Needs Clinic (Hematology). Honors: 600+ transplants for rare diseases & inborn errors of immunity with success above 75%; Vice-Chair, National Health Commission Expert Committee on Childhood Leukemia.
- [Prof. Ge Ming](https://kids.mjktrip.com/en/doctors/ge-ming): Professor · Director, Neurological Center & Neurosurgery — Pediatric Brain Tumors & Epilepsy Surgery. Beijing Children's Hospital, Capital Medical University, Beijing. 35 years of experience. Clinic: Mon AM · Special Needs Clinic (Neurosurgery). Honors: 6,000+ pediatric neurosurgical operations; trained under Academician Wang Zhongcheng; Created an internationally cited vision-oriented classification for optic-pathway glioma (vision preservation 73.8%).
- [Prof. Wang Yi](https://kids.mjktrip.com/en/doctors/wang-yi): Professor · President; Chief of Pediatric Neurology — Pediatric Epilepsy & Neurodevelopmental Disorders. Children's Hospital of Fudan University, Shanghai. 35 years of experience. Clinic: Mon AM · Special Needs Clinic (Neurology). Honors: President, Children's Hospital of Fudan University; Director, National Children's Medical Center (Shanghai); Head, Neurology Group, Chinese Society of Pediatrics (CMA).
- [Prof. Liu Jinfen](https://kids.mjktrip.com/en/doctors/liu-jinfen): Professor · Chief of Cardiothoracic Surgery (former President) — Pediatric Cardiac Surgery (Complex CHD). Shanghai Children's Medical Center, SJTU, Shanghai. 45 years of experience. Clinic: Tue AM · Special Needs Clinic (Cardiac Surgery). Honors: President, CHD Committee of the National Cardiovascular Expert Committee; Mainland China's sole council member, World Society for Pediatric & Congenital Heart Surgery; Deputy Editor, WJPCHS.
- [Prof. Huang Guoying](https://kids.mjktrip.com/en/doctors/huang-guoying): Professor · Pediatric Cardiology (former President) — Pediatric Cardiology & CHD Screening. Children's Hospital of Fudan University, Shanghai. 38 years of experience. Clinic: Wed AM · Special Needs Clinic (Cardiology). Honors: Corresponding author of the landmark 2014 Lancet study on neonatal pulse-oximetry CHD screening — now China's national policy; Landmark Kawasaki disease randomized trial published in the New England Journal of Medicine; further work in Circulation.
- [Prof. Dong Kuiran](https://kids.mjktrip.com/en/doctors/dong-kuiran): Professor · Director, Oncology Surgery — Pediatric Solid Tumor Surgery. Children's Hospital of Fudan University, Shanghai. 28 years of experience. Clinic: Wed AM · Special Needs Clinic (Oncology Surgery). Honors: Vice-Chair, Solid Tumor Group, NHC National Expert Committee on Pediatric Oncology; Standing Committee member & Endoscopic Surgery Group Head, Pediatric Surgery Branch of CMA.
- [Prof. Zhao Peiquan](https://kids.mjktrip.com/en/doctors/zhao-peiquan): Professor · Lead, Retinoblastoma Program — Retinoblastoma & Pediatric Retina. Xinhua Hospital, SJTU School of Medicine, Shanghai. 35 years of experience. Clinic: Mon & Thu AM · Special Needs Clinic (Ophthalmology). Honors: Runs the world's largest retinoblastoma intra-arterial chemotherapy center — survival >99%, eye preservation ~80%; Published in JAMA Ophthalmology & Ophthalmology; identified novel RB-associated genes (JAG1, CTNNA1).
- [Prof. Du Lizhong](https://kids.mjktrip.com/en/doctors/du-lizhong): Professor · Neonatology (former President) — Neonatal Critical Care (PPHN & Preterm Infants). The Children's Hospital, Zhejiang University School of Medicine, Hangzhou. 40 years of experience. Clinic: Wed AM · Special Needs Clinic (Neonatology). Honors: Chaired the Neonatology Group of the Chinese Society of Pediatrics for three consecutive terms (2007–2019); Deputy Editor, BMC Pediatrics; editorial board, The Journal of Pediatrics; 70+ SCI papers.
- [Prof. Xia Huimin](https://kids.mjktrip.com/en/doctors/xia-huimin): Professor · National Chair of Pediatric Surgery (CMA) — Neonatal & Pediatric Surgery. Guangzhou Women & Children's Medical Center, Guangzhou. 40 years of experience. Clinic: Tue AM · Special Needs Clinic (Pediatric Surgery). Honors: President (11th), Pediatric Surgery Branch, Chinese Medical Association; Editor-in-Chief, Chinese Journal of Pediatric Surgery; National referral center for complex congenital malformations — CDH, esophageal atresia, biliary atresia.
- [Prof. Zhao Xiaodong](https://kids.mjktrip.com/en/doctors/zhao-xiaodong): Professor · Party Secretary; Chief of Immunology — Primary Immunodeficiency & Immune Disorders. Children's Hospital of Chongqing Medical University, Chongqing. 30 years of experience. Clinic: Thu AM · Special Needs Clinic (Immunology). Honors: Vice President & Immunology Group Head, Chinese Society of Pediatrics (CMA); 100+ SCI papers in JACI, Blood, Journal of Virology and other international journals.
- [Prof. Mo Xuming](https://kids.mjktrip.com/en/doctors/mo-xuming): Professor · Vice President; Chief of Cardiothoracic Surgery — Pediatric Congenital Heart Surgery. Nanjing Children's Hospital, Nanjing. 35 years of experience. Clinic: Tue AM · Chief Expert Clinic (Cardiothoracic Surgery). Honors: Corresponding author of CHD genetics research in Nature Genetics; National Science & Technology Progress Award (2nd Prize).
- [Prof. Liu Zhisheng](https://kids.mjktrip.com/en/doctors/liu-zhisheng): Professor · Vice President; Chief of Pediatric Neurology — Pediatric Epilepsy & Tic Disorders. Wuhan Children's Hospital, Wuhan. 35 years of experience. Clinic: Wed AM · Renowned Expert Clinic (Neurology). Honors: Vice-Chair, Pediatric Neurology Group, Chinese Society of Pediatrics (CMA); Lead author of China's expert consensus on pediatric tic disorders.
- [Prof. Wen Feiqiu](https://kids.mjktrip.com/en/doctors/wen-feiqiu): Professor · Vice President; Chief of Hematology-Oncology — Childhood Leukemia & HSCT. Shenzhen Children's Hospital, Shenzhen. 35 years of experience. Clinic: Mon AM · Chief Expert Clinic (Hematology-Oncology). Honors: Postdoctoral fellow in pediatric hematology-oncology, RUSH University (USA); Leads South China's largest pediatric HSCT program (26 class-100 laminar-flow units).
- [Prof. Li Long](https://kids.mjktrip.com/en/doctors/li-long): Professor · Chief of Pediatric Surgery — Minimally Invasive Pediatric Surgery. Beijing Tsinghua Changgeng Hospital, Beijing. 40 years of experience. Clinic: Tue AM · Chief Expert Clinic (Pediatric Surgery). Honors: Asia-Pacific President, World Federation of Associations of Pediatric Surgeons (WOFAPS); Asian President, International Pediatric Endosurgery Group (IPEG).

## Partner Hospitals
- [Beijing Children's Hospital, Capital Medical University](https://kids.mjktrip.com/en/hospitals/beijing-childrens): National Children's Medical Center, Beijing. Established 1942; beds 970+; annual patient volume 3,000,000+. Focus: Hematology & Oncology, Neurosurgery, Cellular Therapy. Founded in 1942, Beijing Children's Hospital is China's flagship pediatric institution and the National Children's Medical Center (Beijing). It hosts the national academic leadersh
- [Children's Hospital of Fudan University](https://kids.mjktrip.com/en/hospitals/fudan-childrens): National Children's Medical Center, Shanghai. Established 1952; beds 1,000+; annual patient volume 2,600,000+. Focus: Solid Tumors, Neurology & Epilepsy, Cardiology, Rare Disease. The Children's Hospital of Fudan University is the National Children's Medical Center (Shanghai) — a national academic children's hospital housing national key programs in pediatri
- [Shanghai Children's Medical Center, SJTU](https://kids.mjktrip.com/en/hospitals/shanghai-childrens-medical): National Children's Medical Center, Shanghai. Established 1998; beds 1,300+; annual patient volume 2,000,000+. Focus: Cardiac Surgery, Hematology-Oncology, HSCT & CAR-T. Shanghai Children's Medical Center was jointly built with international partners and is China's benchmark for pediatric cardiac surgery (2,500+ operations/year) and one of the larg
- [Xinhua Hospital, SJTU School of Medicine](https://kids.mjktrip.com/en/hospitals/xinhua-hospital): Grade-A Tertiary · Pediatric Flagship, Shanghai. Established 1958; beds 2,300+; annual patient volume 4,000,000+. Focus: Retinoblastoma, Pediatric Oncology, Perinatal Medicine. Xinhua Hospital's pediatric arm runs the world's largest retinoblastoma intra-arterial chemotherapy program — led by Prof. Zhao Peiquan — achieving survival above 99% with around 8
- [Guangzhou Women & Children's Medical Center](https://kids.mjktrip.com/en/hospitals/guangzhou-women-childrens): National Children's Regional Medical Center, Guangzhou. Established 2006; beds 3,000+; annual patient volume 4,500,000+. Focus: Pediatric Surgery, Fetal Medicine, Southeast Asia Gateway. Guangzhou Women & Children's Medical Center is South China's largest women & children's medical center and the National Children's Regional Medical Center (South-Central). It is ho
- [The Children's Hospital, Zhejiang University School of Medicine](https://kids.mjktrip.com/en/hospitals/zhejiang-childrens): National Clinical Research Center for Child Health, Hangzhou. Established 1951; beds 2,900+; annual patient volume 4,000,000+. Focus: Neonatology, Pediatric ICU, National Research Center. The Children's Hospital of Zhejiang University School of Medicine is the National Clinical Research Center for Child Health & Disease — China's academic home of neonatology, led fo
- [Children's Hospital of Chongqing Medical University](https://kids.mjktrip.com/en/hospitals/chongqing-childrens): National Children's Regional Medical Center, Chongqing. Established 1956; beds 2,480+; annual patient volume 3,600,000+. Focus: Clinical Immunology, NICU / ECMO, Rare Disease. The Children's Hospital of Chongqing Medical University is the National Children's Regional Medical Center (Southwest) and China's academic leader in pediatric clinical immunology.
- [West China Second University Hospital, SCU](https://kids.mjktrip.com/en/hospitals/west-china-second): National Children's Regional Medical Center, Chengdu. Established 1896; beds 2,580+; annual patient volume 3,000,000+. Focus: Rare Diseases, Genetics Lab, Fetal & Neonatal. West China Second University Hospital (Sichuan University) is a National Children's Regional Medical Center and a women & children's academic center, home to a national-level rare 
- [Beijing Jingdu Children's Hospital](https://kids.mjktrip.com/en/hospitals/beijing-jingdu-childrens): Private Grade-III Children's Specialty Hospital, Beijing. Established 2015; beds 500+; annual patient volume 300,000+. Focus: Hematology & HSCT Flagship, 19 Class-100 Clean Units, Comfort Care. Beijing Jingdu Children's Hospital is a private Grade-III children's specialty hospital. Its Hematology-Oncology Center — led by Prof. Wu Minyuan and President Sun Yuan — is a nati
- [Beijing New Century Children's Hospital](https://kids.mjktrip.com/en/hospitals/new-century-childrens): Premium Private Children's Hospital, Beijing. Established 2006; beds 100+; annual patient volume 100,000+. Focus: Beijing Children's Hospital Partnership, International Insurance, 24/7 Pediatric ER. Beijing New Century Children's Hospital is a premium private children's hospital in long-term public-private partnership with Beijing Children's Hospital (since 2006). Senior publi
- [Shanghai United Family Hospital](https://kids.mjktrip.com/en/hospitals/shanghai-united-family): JCI-Accredited International Hospital, Shanghai. Established 2004; beds 200+; annual patient volume 200,000+. Focus: JCI Accredited, International Pediatrics, 16 Languages. Shanghai United Family Hospital is Shanghai's benchmark international hospital — continuously JCI-accredited — with an internationally trained pediatrics department, 24/7 pediatric
- [Nanjing Children's Hospital](https://kids.mjktrip.com/en/hospitals/nanjing-childrens): National Children's Regional Medical Center, Nanjing. Established 1953; beds 1,742; annual patient volume 3,000,000+. Focus: Est. 1953, Regional Center (East China), Cardiac Surgery Powerhouse. Founded in 1953, Nanjing Children's Hospital (Nanjing Medical University) is a National Children's Regional Medical Center serving East China — 1,742 beds and over 3 million outpat
- [Wuhan Children's Hospital](https://kids.mjktrip.com/en/hospitals/wuhan-childrens): Hubei Provincial Children's Medical Center, Wuhan. Established 1954; beds 2,660; annual patient volume 3,070,000+. Focus: Est. 1954, Three Campuses, Neurology Leadership. Founded in 1954, Wuhan Children's Hospital is one of New China's first children's hospitals — affiliated with Tongji Medical College (HUST), 2,660 beds across three campuses, and d
- [Shenzhen Children's Hospital](https://kids.mjktrip.com/en/hospitals/shenzhen-childrens): Grade-A Tertiary Children's Hospital (Guangdong's First), Shenzhen. Established 1997; beds 1,331; annual patient volume 2,490,000+. Focus: Est. 1997, South China HSCT Center, Greater Bay Area. Shenzhen Children's Hospital, founded in 1997, is Guangdong's first Grade-A tertiary children's hospital — 1,331 beds at the Futian campus plus the new Longhua campus, serving 2.49
- [Beijing Tsinghua Changgeng Hospital](https://kids.mjktrip.com/en/hospitals/beijing-tsinghua-changgeng): Tsinghua University Affiliated Tertiary Hospital, Beijing. Established 2014; beds 1,000+; annual patient volume 1,500,000+. Focus: Tsinghua University, Pediatric Surgery Center, Est. 2014. Beijing Tsinghua Changgeng Hospital is Tsinghua University's affiliated tertiary hospital (opened 2014). Its pediatric surgery center, founded and led by Prof. Li Long — Asia-Pacif

## Treatments & Technologies
- [Pediatric CAR-T Cell Therapy](https://kids.mjktrip.com/en/technologies/pediatric-car-t) (Cellular Therapy, NMPA-approved products · Extensive pediatric trial network): China runs the world's largest pediatric CAR-T clinical program — CD19/CD22 products achieve >90% complete remission in relapsed/refractory childhood B-ALL, at roughly one third of Western costs. Complete remission (r/r B-ALL): >90%; Children treated (program): 800+; Typical cost vs US: ~1/3. For: Leukemia, Lymphoma.
- [Pediatric Stem Cell Transplant (HSCT)](https://kids.mjktrip.com/en/technologies/pediatric-hsct) (Cellular Therapy, Mature clinical use · National transplant centers): Haploidentical transplant protocols pioneered in China enable virtually every child to find a donor — curative for leukemia, thalassemia and immune deficiencies, with outcomes matching matched-sibling transplants. Donor availability: ~100% (haplo); Thalassemia cure rate: >90%; Wait for donor search: 2–4 weeks. For: Leukemia, Thalassemia, Lymphoma.
- [Proton Therapy for Children](https://kids.mjktrip.com/en/technologies/proton-therapy) (Particle Therapy, Mature clinical use · Pediatric anesthesia team): Proton beam spares growing tissues — critical for children with brain tumors and sarcomas. Shanghai's proton & heavy-ion center operates dedicated pediatric protocols with anesthesia support for young children. Dose to healthy tissue: ↓ up to 60%; Patients treated (center): 10,000+; Average course cost: ~RMB 278k. For: Brain tumor, Bone sarcoma, Retinoblastoma, Neuroblastoma.
- [Intra-Arterial Chemotherapy for Retinoblastoma](https://kids.mjktrip.com/en/technologies/retinoblastoma-iac) (Interventional Oncology, Mature clinical use · Eye-preservation programs): Superselective intra-arterial chemotherapy delivers drug directly to the eye — saving both life and sight. The Xinhua Hospital program reports >99% survival with ~80% eye preservation. Survival (program): >99%; Eye preservation: ~80%; Systemic side effects: Minimal. For: Retinoblastoma.
- [Gene & Rare Disease Therapies](https://kids.mjktrip.com/en/technologies/gene-therapy-rare) (Innovative Therapy, NRDL-covered · Boao Lecheng early access): From nusinersen to base-editing trials for thalassemia, innovative rare disease therapies are increasingly accessible in China through national reimbursement and the Boao Lecheng pilot zone. SMA children treated: 300+; Genomic diagnosis time: ~2 weeks; Cost after NRDL: ↓ ~70%. For: Rare disease.
- [Advanced Pediatric Cardiac Surgery](https://kids.mjktrip.com/en/technologies/pediatric-cardiac-surgery) (Surgery, Mature clinical use · High-volume centers): Neonatal arterial switch, single-ventricle staging and minimally invasive repair — China's top centers operate on newborns as small as 2 kg with >98% survival for complex defects. Complex CHD survival: >98%; Annual operations: 2,500+; Smallest patients: 2.1 kg. For: Congenital heart disease.
- [Pediatric Epilepsy Surgery & VNS](https://kids.mjktrip.com/en/technologies/epilepsy-surgery) (Neurosurgery, Comprehensive epilepsy centers): Stereo-EEG guided resection, laser ablation and vagus nerve stimulation give drug-resistant epilepsy children a real chance at seizure freedom. Annual pre-surgical evaluations: 500+; Seizure freedom/reduction: >65%; Minimally invasive options: LITT / VNS. For: Epilepsy.
- [Neonatal Intensive Care & ECMO](https://kids.mjktrip.com/en/technologies/nicu-ecmo) (Critical Care, National NICU network · ECMO transport teams): Level III NICUs rescue extremely preterm infants from 24 weeks — with therapeutic hypothermia, neonatal surgery and inter-hospital ECMO transport. Smallest survivors: 560 g / 24 wk; ELBW survival: >80%; NICU beds (largest): 200. For: Neonatal care.
- [Pediatric Precision Imaging](https://kids.mjktrip.com/en/technologies/precision-imaging-peds) (Diagnostics, Installed at national children's centers): Ultra-low-dose pediatric protocols on total-body PET-CT and 3T MRI — child-friendly suites with sedation teams make scans safer and calmer. Tracer dose reduction: up to 40x; Report turnaround: 24–48 h; Sedation team: Dedicated. For: Leukemia, Lymphoma, Neuroblastoma, Brain tumor, Bone sarcoma.

## Innovative Medicines
- Blinatumomab (Immunotherapy (BiTE)): for Relapsed/refractory childhood B-ALL; MRD-positive ALL. Target: CD19 × CD3 bispecific T-cell engager (BiTE). First approved: US FDA · 2014; NMPA · 2020. Maturity: NMPA approved · childhood r/r B-ALL indication. Price & coverage: Imported originator; partial commercial-insurance & Huiminbao coverage. [List page](https://kids.mjktrip.com/en/drugs#blinatumomab)
- Dinutuximab (GD2 antibody) (Immunotherapy): for High-risk neuroblastoma maintenance. Target: GD2 disialoganglioside (anti-GD2 monoclonal antibody). First approved: US FDA · 2015; NMPA · 2021. Maturity: NMPA approved · high-risk neuroblastoma maintenance. Price & coverage: High-cost import; Lecheng early-access & charity programs available. [List page](https://kids.mjktrip.com/en/drugs#dinutuximab)
- Nusinersen (Rare disease (ASO)): for Spinal muscular atrophy (SMA) all types. Target: SMN2 pre-mRNA splicing modifier (antisense oligonucleotide). First approved: US FDA · 2016; NMPA · 2019. Maturity: NMPA approved · listed in China NRDL (2021 negotiation). Price & coverage: NRDL-negotiated — per-dose cost cut from ~¥700K to ~¥33K. [List page](https://kids.mjktrip.com/en/drugs#nusinersen)
- CD19 CAR-T Products (CN) (Cellular therapy): for Relapsed/refractory B-cell leukemia & lymphoma. Target: CD19 (B-cell surface antigen), autologous CAR-T. First approved: NMPA · 2021 (first CAR-T in China); pediatric B-ALL product · 2025. Maturity: NMPA approved · incl. product indicated for ages 3–21 r/r B-ALL. Price & coverage: ≈ ¥1.0–1.3M per course; Huiminbao & commercial plans partly cover. [List page](https://kids.mjktrip.com/en/drugs#cd19-car-t-products)
- Pegaspargase (Enzyme therapy): for Childhood ALL backbone therapy. Target: Asparagine depletion (PEGylated L-asparaginase). First approved: NMPA · 2009 (China-originated long-acting formulation). Maturity: NMPA approved · backbone of CCLG childhood ALL protocols. Price & coverage: NRDL listed — a fraction of imported asparaginase cost. [List page](https://kids.mjktrip.com/en/drugs#pegaspargase)
- Imatinib (CN generics) (Targeted therapy): for Ph+ ALL, CML in children. Target: BCR-ABL tyrosine kinase inhibitor. First approved: US FDA · 2001 (originator); CN generics · 2013+. Maturity: Generics passed national quality & consistency evaluation. Price & coverage: NRDL listed generic — annual cost in the low-thousands RMB. [List page](https://kids.mjktrip.com/en/drugs#imatinib-generics)
- Sirolimus (mTOR inhibitor): for Vascular anomalies, LAM, refractory immune cytopenia. Target: mTOR (mechanistic target of rapamycin) inhibitor. First approved: US FDA · 1999; pediatric vascular-anomaly use guideline-supported. Maturity: NMPA approved · routine off-label pathways in national centers. Price & coverage: NRDL listed; low monthly cost versus imported biologics. [List page](https://kids.mjktrip.com/en/drugs#sirolimus)
- Caffeine Citrate (Neonatal care): for Apnea of prematurity. Target: Adenosine receptor antagonist (respiratory stimulant). First approved: US FDA · 1999; NMPA approved & NRDL listed. Maturity: Global NICU standard of care for apnea of prematurity. Price & coverage: Low-cost essential medicine, reimbursed in China. [List page](https://kids.mjktrip.com/en/drugs#caffeine-citrate)
- Risdiplam (Evrysdi) (Rare disease · SMA): for Spinal muscular atrophy (16 days of age and older). Target: SMN2 pre-mRNA splicing modifier (raises functional SMN protein). First approved: NMPA · 2021; indication extended to ≥16-day-old infants in 2023. Maturity: NRDL listed — home oral alternative to intrathecal nusinersen. Price & coverage: NRDL negotiated — transformative cost reduction vs. launch price. [List page](https://kids.mjktrip.com/en/drugs#risdiplam)
- Selumetinib (Koselugo) (Rare disease · Targeted therapy): for NF1-related symptomatic, inoperable plexiform neurofibromas (≥3 yrs). Target: MEK1/2 inhibitor (MAPK pathway). First approved: NMPA · 2023 (priority review; first-in-class for NF1-PN). Maturity: NMPA approved · NRDL listed for children ≥3 years. Price & coverage: NRDL negotiated — first reimbursed NF1-PN targeted therapy in China. [List page](https://kids.mjktrip.com/en/drugs#selumetinib)
- Larotrectinib (Vitrakvi) (Precision oncology): for NTRK fusion–positive solid tumors (all ages, incl. newborns). Target: TRK A/B/C (NTRK gene fusion). First approved: NMPA · 2022 (capsules + pediatric oral solution). Maturity: NMPA approved · only all-age TRK inhibitor with neonatal indication in China. Price & coverage: Imported innovative drug; patient assistance programs available. [List page](https://kids.mjktrip.com/en/drugs#larotrectinib)
- Stiripentol (Diacomit) (Rare epilepsy): for Dravet syndrome (≥6 months, with valproate + clobazam). Target: GABAergic modulation + CYP-mediated synergy with clobazam. First approved: NMPA · 2023 (China's first Dravet-specific approval). Maturity: NMPA approved · guideline-endorsed add-on for Dravet syndrome. Price & coverage: Imported orphan drug; reimbursement access expanding. [List page](https://kids.mjktrip.com/en/drugs#stiripentol)
- Emicizumab (Hemlibra) (Hematology · Bispecific antibody): for Hemophilia A with factor VIII inhibitors (incl. infants). Target: FIXa × FX bispecific antibody (FVIIIa mimetic). First approved: NMPA · 2018 (first bispecific for hemophilia A in China). Maturity: NMPA approved · global standard prophylaxis including children. Price & coverage: Imported biologic; patient-assistance programs for eligible families. [List page](https://kids.mjktrip.com/en/drugs#emicizumab)
- Alglucosidase Alfa (Myozyme) (Rare disease · ERT): for Pompe disease (incl. infantile-onset). Target: Recombinant acid α-glucosidase (GAA) replacement. First approved: NMPA · 2015 (first Pompe ERT in China). Maturity: NMPA approved; long-term real-world use in Chinese Pompe centers. Price & coverage: Imported ERT; select provincial rare-disease support schemes. [List page](https://kids.mjktrip.com/en/drugs#alglucosidase-alfa)
- Idursulfase Beta (Hunterase) (Rare disease · ERT): for Mucopolysaccharidosis type II (Hunter syndrome). Target: Iduronate-2-sulfatase (I2S) replacement. First approved: NMPA · 2020 (first MPS II therapy in China). Maturity: NMPA approved; administered in national rare-disease centers. Price & coverage: Imported ERT; select provincial coverage pilots. [List page](https://kids.mjktrip.com/en/drugs#idursulfase-beta)
- Agalsidase Beta (Fabrazyme) (Rare disease · ERT): for Fabry disease (incl. adolescents). Target: Recombinant α-galactosidase A replacement. First approved: NMPA · 2019. Maturity: NMPA approved · NRDL listed (2021 negotiation). Price & coverage: NRDL negotiated — annual cost cut to a fraction of list price. [List page](https://kids.mjktrip.com/en/drugs#agalsidase-beta)

## Recovery Stories (anonymized, published with family consent)
- [Back to the Playground: Mila’s CAR-T Story](https://kids.mjktrip.com/en/cases/mila-car-t-remission): condition Leukemia. After her leukemia relapsed twice, Mila’s family flew from Moscow for CD19 CAR-T therapy. She reached complete remission within 28 days.
- [One Transplant, A Life Without Transfusions](https://kids.mjktrip.com/en/cases/daniyar-thalassemia-cure): condition Thalassemia. Daniyar depended on blood transfusions every three weeks since infancy. A haploidentical transplant from his mother freed him from them for good.
- [A Newborn Heart, Repaired at 19 Days Old](https://kids.mjktrip.com/en/cases/naya-heart-switch): condition Congenital heart disease. Born with transposition of the great arteries, Naya was air-transferred to Shanghai at two weeks old for a neonatal arterial switch — and went home with a whole heart.
- [Saving Sight: Omar’s Retinoblastoma Journey](https://kids.mjktrip.com/en/cases/omar-eye-saved): condition Retinoblastoma. Doctors at home recommended removing Omar’s left eye. A Shanghai program treated the tumor through a hair-thin catheter instead — and saved his sight.
- [Seizure-Free After 200 Seizures a Month](https://kids.mjktrip.com/en/cases/temuulen-epilepsy-free): condition Epilepsy. Temuulen’s drug-resistant epilepsy resisted four medications. Robotic stereo-EEG found the source; a small, precise resection ended the seizures.
- [Born at 26 Weeks, Home for Tet](https://kids.mjktrip.com/en/cases/linh-nicu-survival): condition Neonatal care. Born extremely early during a family trip, Linh spent twelve weeks in a Chongqing NICU — and went home in time for the Lunar New Year.

## Frequently Asked Questions
- Q: How much does CAR-T therapy cost for a child in China?
  A: At our partner children's centers, pediatric CAR-T cell therapy typically costs between US$45,000 and US$70,000, including cell manufacturing and hospitalization — a fraction of US or European prices. An exact quote is provided after a free case review of your child's records.
- Q: How do I request a free case review?
  A: Fill in the case review form on this page with your child's diagnosis and a short medical summary. Our pediatric coordination team responds within 24 hours with recommended hospitals, specialists and an estimated treatment plan and cost.
- Q: Which children's hospitals do you work with?
  A: We partner with National Children's Medical Centers and Grade-A tertiary children's hospitals, including Beijing Children's Hospital (Capital Medical University) and other pediatric centers across China.
- Q: Do you support families who don't speak Chinese?
  A: Yes. Every family gets a dedicated coordinator, professional medical interpreters (English/Russian), translated medical records and 7-day WhatsApp support at +86 138 1783 1623 throughout the stay.
- Q: How long does treatment in China usually take?
  A: It depends on the therapy: CAR-T usually takes 4–6 weeks (evaluation, infusion and monitoring), bone marrow transplant 1.5–3 months, and cardiac surgery about 2–4 weeks. We arrange medical visas, airport pickup and family accommodation.
- Q: Is my child's medical information kept private?
  A: Absolutely. Case details are reviewed only by our medical coordination team and the partner physicians involved. Recovery stories published on this site are anonymized and shared with the family's written consent.

## Policies & Notes
- Medical disclaimer: site content is informational and does not constitute a medical diagnosis.
- Recovery stories are anonymized; names are pseudonyms used with family consent.
- Sitemap: https://kids.mjktrip.com/sitemap.xml
- Short version: https://kids.mjktrip.com/llms.txt